Bictegravir is an HIV integrase strand-transfer inhibitor incorporated into single-tablet antiretroviral regimens, blocking viral DNA integration into the host genome. Simson Pharma's Bictegravir reference standard and impurities support stability-indicating method development for this modern antiretroviral combination.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Bictegravir Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.